Pembrolizumab in lung cancer

current evidence and future perspectives

Giuliano Palumbo, Guido Carillio, Anna Manzo, Agnese Montanino, Vincenzo Sforza, Raffaele Costanzo, Claudia Sandomenico, Carmine La Manna, Giuseppe De Luca, Maria Carmela Piccirillo, Gennaro Daniele, Rossella De Cecio, Gerardo Botti, Giuseppe Totaro, Paolo Muto, Carmine Picone, Giovanna Esposito, Nicola Normanno, Alessandro Morabito

Research output: Contribution to journalArticle

Abstract

Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.

Original languageEnglish
JournalFuture Oncology
DOIs
Publication statusE-pub ahead of print - Aug 21 2019

Fingerprint

Lung Neoplasms
Ligands
Non-Small Cell Lung Carcinoma
Antibodies, Monoclonal, Humanized
Biological Factors
Platinum
Oncogenes
Radiotherapy
Randomized Controlled Trials
pembrolizumab

Cite this

Pembrolizumab in lung cancer : current evidence and future perspectives. / Palumbo, Giuliano; Carillio, Guido; Manzo, Anna; Montanino, Agnese; Sforza, Vincenzo; Costanzo, Raffaele; Sandomenico, Claudia; Manna, Carmine La; Luca, Giuseppe De; Piccirillo, Maria Carmela; Daniele, Gennaro; Cecio, Rossella De; Botti, Gerardo; Totaro, Giuseppe; Muto, Paolo; Picone, Carmine; Esposito, Giovanna; Normanno, Nicola; Morabito, Alessandro.

In: Future Oncology, 21.08.2019.

Research output: Contribution to journalArticle

@article{4f792b88da834efe9a9241a89865040a,
title = "Pembrolizumab in lung cancer: current evidence and future perspectives",
abstract = "Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1{\%} (KEYNOTE-010), in first-line setting PD-L1 ≥50{\%} (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.",
author = "Giuliano Palumbo and Guido Carillio and Anna Manzo and Agnese Montanino and Vincenzo Sforza and Raffaele Costanzo and Claudia Sandomenico and Manna, {Carmine La} and Luca, {Giuseppe De} and Piccirillo, {Maria Carmela} and Gennaro Daniele and Cecio, {Rossella De} and Gerardo Botti and Giuseppe Totaro and Paolo Muto and Carmine Picone and Giovanna Esposito and Nicola Normanno and Alessandro Morabito",
year = "2019",
month = "8",
day = "21",
doi = "10.2217/fon-2019-0073",
language = "English",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Pembrolizumab in lung cancer

T2 - current evidence and future perspectives

AU - Palumbo, Giuliano

AU - Carillio, Guido

AU - Manzo, Anna

AU - Montanino, Agnese

AU - Sforza, Vincenzo

AU - Costanzo, Raffaele

AU - Sandomenico, Claudia

AU - Manna, Carmine La

AU - Luca, Giuseppe De

AU - Piccirillo, Maria Carmela

AU - Daniele, Gennaro

AU - Cecio, Rossella De

AU - Botti, Gerardo

AU - Totaro, Giuseppe

AU - Muto, Paolo

AU - Picone, Carmine

AU - Esposito, Giovanna

AU - Normanno, Nicola

AU - Morabito, Alessandro

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.

AB - Pembrolizumab is a humanized monoclonal antibody against PD-1 capable of enhancing antitumor immune activity. The KEYNOTE-001 study showed that pembrolizumab has activity in advanced non-small-cell lung cancer patients and identified programmed death ligand 1 (PD-L1) as a companion test to select patients most likely to benefit from pembrolizumab. Five randomized clinical trials showed the efficacy of pembrolizumab in non-small-cell lung cancer: in second-line setting PD-L1 ≥1% (KEYNOTE-010), in first-line setting PD-L1 ≥50% (KEYNOTE-024 and KEYNOTE-042) and in first-line setting in combination with platinum doublets, any expression of PD-L1 (KEYNOTE-189 and KEYNOTE-407). Future challenges are the identification of the role of pembrolizumab in adjuvant, neoadjuvant, locally advanced disease or oncogene-addicted patients, in combination with radiotherapy or other biological agents.

U2 - 10.2217/fon-2019-0073

DO - 10.2217/fon-2019-0073

M3 - Article

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -